000128100 001__ 128100
000128100 005__ 20240228145534.0
000128100 0247_ $$2doi$$a10.3324/haematol.2017.168005
000128100 0247_ $$2pmid$$apmid:28495913
000128100 0247_ $$2pmc$$apmc:PMC5541876
000128100 0247_ $$2ISSN$$a0390-6078
000128100 0247_ $$2ISSN$$a1592-8721
000128100 0247_ $$2altmetric$$aaltmetric:20149020
000128100 037__ $$aDKFZ-2017-04122
000128100 041__ $$aeng
000128100 082__ $$a610
000128100 1001_ $$aMerz, Maximilian$$b0
000128100 245__ $$aLongitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation.
000128100 260__ $$aPavia$$bFerrata Storti Foundation$$c2017
000128100 3367_ $$2DRIVER$$aarticle
000128100 3367_ $$2DataCite$$aOutput Types/Journal article
000128100 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1660826877_27718
000128100 3367_ $$2BibTeX$$aARTICLE
000128100 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000128100 3367_ $$00$$2EndNote$$aJournal Article
000128100 520__ $$aTo investigate cytogenetic evolution after upfront autologous stem cell transplantation for newly diagnosed myeloma we retrospectively analyzed fluorescence in situ hybridization results of 128 patients with paired bone marrow samples from the time of primary diagnosis and at relapse. High-risk cytogenetic abnormalities (deletion 17p and/or gain 1q21) occurred more frequently after relapse (odds ratio: 6.33; 95% confidence interval: 1.86-33.42; P<0.001). No significant changes were observed for defined IGH translocations [t(4;14); t(11;14); t(14;16)] or hyperdiploid karyotypes between primary diagnosis and relapse. IGH translocations with unknown partners occurred more frequently at relapse. New deletion 17p and/or gain 1q21 were associated with cytogenetic heterogeneity, since some de novo lesions with different copy numbers were present only in subclones. No distinct baseline characteristics were associated with the occurrence of new high-risk cytogenetic abnormalities after progression. Patients who relapsed after novel agent-based induction therapy had an increased risk of developing high-risk aberrations (odds ratio 10.82; 95% confidence interval: 1.65-127.66; P=0.03) compared to those who were treated with conventional chemotherapy. Survival analysis revealed dismal outcomes regardless of whether high-risk aberrations were present at baseline (hazard ratio, 3.53; 95% confidence interval: 1.53-8.14; P=0.003) or developed at relapse only (hazard ratio, 3.06; 95% confidence interval: 1.09-8.59; P=0.03). Our results demonstrate cytogenetic evolution towards high-risk disease after autologous transplantation and underline the importance of repeated genetic testing in relapsed myeloma (EudraCT number of the HD4 trial: 2004-000944-26).
000128100 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000128100 588__ $$aDataset connected to CrossRef, PubMed,
000128100 7001_ $$aJauch, Anna$$b1
000128100 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b2
000128100 7001_ $$aMai, Elias K$$b3
000128100 7001_ $$aSeckinger, Anja$$b4
000128100 7001_ $$aHose, Dirk$$b5
000128100 7001_ $$aBertsch, Uta$$b6
000128100 7001_ $$aNeben, Kai$$b7
000128100 7001_ $$0P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3$$aRaab, Marc-Steffen$$b8
000128100 7001_ $$aSalwender, Hans$$b9
000128100 7001_ $$aBlau, Igor W$$b10
000128100 7001_ $$aLindemann, Hans-Walter$$b11
000128100 7001_ $$aSchmidt-Wolf, Ingo$$b12
000128100 7001_ $$aScheid, Christof$$b13
000128100 7001_ $$aHaenel, Mathias$$b14
000128100 7001_ $$aWeisel, Katja$$b15
000128100 7001_ $$0P:(DE-He78)a1aa959d47e3e026abe157a8adf24b96$$aGoldschmidt, Hartmut$$b16
000128100 7001_ $$0P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5$$aHillengass, Jens$$b17$$eLast author
000128100 773__ $$0PERI:(DE-600)2805244-4$$a10.3324/haematol.2017.168005$$gVol. 102, no. 8, p. 1432 - 1438$$n8$$p1432 - 1438$$tHaematologica$$v102$$x1592-8721$$y2017
000128100 909CO $$ooai:inrepo02.dkfz.de:128100$$pVDB
000128100 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000128100 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000128100 9101_ $$0I:(DE-HGF)0$$6P:(DE-He78)a1aa959d47e3e026abe157a8adf24b96$$aExternal Institute$$b16$$kExtern
000128100 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000128100 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000128100 9141_ $$y2017
000128100 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000128100 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000128100 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000128100 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000128100 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000128100 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000128100 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000128100 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000128100 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000128100 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000128100 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000128100 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000128100 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000128100 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x0
000128100 9201_ $$0I:(DE-He78)G170-20160331$$kG170$$lExperimentelle Therapien hämatologischer Neoplasien$$x1
000128100 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x2
000128100 980__ $$ajournal
000128100 980__ $$aVDB
000128100 980__ $$aI:(DE-He78)C060-20160331
000128100 980__ $$aI:(DE-He78)G170-20160331
000128100 980__ $$aI:(DE-He78)E010-20160331
000128100 980__ $$aUNRESTRICTED